A lawyer who assembled a whistleblower lawsuit against a major pharmaceutical company using publicly available patent board filings argued that the broader legal question of whether this method is permissible is too specialized for the Supreme Court to consider. The case hinges on the use of these filings in forming the basis of the lawsuit under the False Claims Act (FCA), which has significant implications for future whistleblower cases relying on public documents.
For further details, you can read the original article on Law360.